GlassScriptPhysician profile
Benjamin A Laracuente
NPI 1336146968
$1,560.61
in general payments reported to CMS, 2019-2025
20 companies · $343 in 2025
The $343 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $31.73 · 2020: $84.70 · 2021: $706 · 2022: $187 · 2023: $189 · 2024: $18.23 · 2025: $343.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $551.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $550.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $427.53 | 2020-2025 | Breztri |
| Glaxosmithkline, LLC. | $408.03 | 2021-2025 | Trelegy Ellipta, Nucala |
| Grifols USA, LLC | $142.49 | 2019-2021 | |
| Genzyme Corporation | $105.77 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $67.36 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $66.17 | 2021-2023 | |
| Novo Nordisk INC | $40.50 | 2021 | |
| Verona Pharma, INC. | $39.76 | 2025 | Ohtuvayre |
| Regeneron Healthcare Solutions, INC. | $37.80 | 2025 | Dupixent |
| Teva Pharmaceuticals USA, INC. | $37.29 | 2021 | |
| Advanced Respiratory, INC | $36.25 | 2021 | |
| Pulmonx Corporation | $32.43 | 2025 | Chartis Catheter, Zephyr Endobronchial Valve, Zephyr Delivery Catheter |
| Actelion Pharmaceuticals US, INC. | $20.60 | 2021 | |
| Mylan Specialty L.P. | $19.63 | 2021 | |
| Lilly USA, LLC | $17.98 | 2025 | Zepbound |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insmed, INC. | $16.24 | 2021 | |
| Jazz Pharmaceuticals INC. | $13.86 | 2021 | |
| Electromed, INC. | $13.11 | 2024 | Smartvest |
| Harmony Biosciences LLC | $12.69 | 2022 | |
| Inogen, INC. | $5.12 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Laracuente listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.